| Literature DB >> 27924157 |
Changho Lee1, Woosung Kwon2, Songeun Beack3, Donghyun Lee4, Yoonsang Park5, Hyemin Kim3, Sei Kwang Hahn3, Shi-Woo Rhee6, Chulhong Kim4.
Abstract
Multifunctional nanoparticles have been widely investigated for biomedical applications, such as imaging, therapy, and drug delivery. Especially, photoactive nanoparticles have received great attention as theranostic agents because of their heat-geneEntities:
Keywords: Biodegradation.; Carbon nanodot; Nitrogen doping; Photoacoustic; Photothermal
Mesh:
Substances:
Year: 2016 PMID: 27924157 PMCID: PMC5135443 DOI: 10.7150/thno.16923
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
Figure 1Synthesis of N-CNDs and effect of nitrogen doping. (a) Synthesis of N-CNDs. (b) TEM image of N-CNDs (scale bar = 5 nm). (c) Partial graphitic structures in the core of N-CNDs (scale bar = 2 nm). (d) Illustration of electronic structures and nitrogen-induced intra-gap states of N-CNDs. (e) Optical absorption spectrum of N-CNDs as a function of nitric acid concentration. (f) PA amplitude spectrum with different N-doped CNDs. HOMO, highest occupied molecular orbital; LUMO, lowest unoccupied molecular orbital.
Figure 2Photoacoustic (PA) and photothermal characteristics of N-CNDs. (a) PA signal amplitude comparison of GNR, MB, and N-CNDs at the same optical density. (b) The stability of the PA responses of GNR, MB, and N-CNDs depending on the number of pulses of laser irradiation. (c) Optical absorption measurement of GNR and N-CNDs with and without laser irradiation. (d) Temperature elevation curves of N-CNDs at different concentrations (0, 0.1, 0.25, 0.5, 1, 2.5, 5, 10, 20 mg/mL). GNR, gold nanorod; MB, methylene blue.
Figure 3(a) PA maximum amplitude projection (MAP) image before N-CNDs injection. (b) PA MAP image 30 min after N-CNDs injection. (c) PA MAP image after 150 min of N-CNDs injection. (d) Depth-encoded PA MAP image after 30 min of N-CNDs injection. (e-g) Corresponding PA B-mode images of the dashed line area in (a-c). (h) PA signal profile in the SLN region from before injection to 180 min after the N-CNDs injection. (i) and (j) Photograph and PA MAP image, respectively, of SLNs excised after the N-CNDs injection (L1-L3) and control (L4-L6). (k) PA signal of the excised SLNs. SLN, sentinel lymph node; L, lymph node.
Figure 4(a) Coronal (front) PA maximum amplitude projection (MAP) image before N-CNDs injection. (b) and (c) Coronal PA MAP image after 100 min and 450 min of N-CNDs injection. (d-f) Corresponding PA B-mode images at the dashed line region of (a-c). (g-i) Corresponding depth-encoded PA MAP images of the PA MAP images of (a-c). (j) and (k) PA signal profile in the bladder region (white dashed circle in (a-c)) and injected area (red dashed circle in (a-c)) from before injection to 500 min after the N-CNDs injection. (l) and (m) Serum biochemistry assay of N-CNDs-injected mice.
Figure 5Photothermal therapy (PTT) using N-CNDs (a) Thermal camera images of N-CNDs injection with NIR laser irradiation. (b) Temperature profile of the injected area with and without NIR laser irradiation. (c) and (d) PTT monitoring and tumor volume profile of PBS and N-CNDs-injected models. (e) Histological analysis of tumor tissues with H&E staining and TUNEL assay 12 hours after PBS and N-CNDs injection without and with NIR laser irradiation. (black scale bar = 100 µm, white scale bar = 1000 µm).